Hongqi Pharmaceutical
HONGQI PHARMACEUTICAL
Cherish life, pay attention to health.
CHERISH LIFE CARE ABOUT HEALTH
Talk about the old and learn about the new, eclectic
Category:
Company News
Author:
Source:
Add time:2019-05-08 13:32
The 11th Council of the Chinese Tuberculosis Association Tuberculosis Clinical Professional Branch
----The first academic forum of the inaugural meeting and the clinical professional branch in 2019
On April 12, 2019, the 2019 General Assembly of the Eleventh Council of the Tuberculosis Clinical Professional Branch of the Chinese Antituberculosis Association and the first academic forum of the Clinical Professional Branch were held in Yanji City, Jilin Yanbian Korean Autonomous Prefecture. Xu Shaofa, vice chairman of the Chinese Antituberculosis Association, Cheng Shiming, secretary general, and more than one hundred members of the clinical professional branch attended the meeting. Professor Lu Yu from the Institute of Materia Medica of Beijing Chest Hospital was invited by the company to give a speech on "Anti-tuberculosis drug Rifampicin Capsule II", introducing the R&D and application of Hongqi Pharmaceutical Rifampicin Capsule II and the preliminary conclusions of multi-center clinical research trials. , And Hongqi Pharmaceutical's achievements in the consistency evaluation of generic drugs have won unanimous praise from the participating experts.
The meeting was divided into two parts. The morning agenda was the 2019 inauguration meeting of the 11th Council of the Chinese Tuberculosis Clinical Professional Branch of the China National Tuberculosis Association. The meeting was chaired by Professor Duan Hongfei, the new secretary-general of the Clinical Professional Branch, Beijing Chest Hospital. Xu Shaofa, vice chairman of the Tuberculosis Association, made an opening speech. Jin Xin, the leader of the Health Committee of Yanbian Korean Autonomous Prefecture of Jilin Province, and Yu Jinglai, the director of Jilin Tuberculosis Hospital, as host representatives, welcomed the experts to Yanji, the hometown of Jindalaihua. Subsequently, Secretary-General Cheng Shiming of the China National Tuberculosis Association announced the "Decision of the China National Tuberculosis Association on Approving the Re-election of Branches". Professor Li Qi of Beijing Chest Hospital, chairman of the previous clinical branch, made a summary of the branch's work for 2016-2019. In the report, Professor Chen Xiaoyou, the chairman of the Beijing Chest Hospital, made a report on the preparatory work of the branch in 2019. Then, the vice chairman Xu Shaofa read out the election method of the members, the vice chairman and the chairman, and all the members voted to elect Professor Chen Xiaoyou as the chairman of the clinical professional branch. Professor Liu Jincheng and ten other members were the deputy directors, and Professor Duan Hongfei was the vice chairman. Secretary General.
The afternoon agenda was the first academic forum of the clinical professional branch. Professor Li Qi, Professor Chen Xiaoyou and other experts gave professional academic reports on the progress and challenges of tuberculosis diagnosis and treatment, and the treatment of multidrug-resistant tuberculosis from different professional perspectives. Professor Lu Yu from the Drug Research Office of Beijing Chest Hospital has been engaged in the clinical and basic research of tuberculosis for more than 20 years, and has always been committed to the research of anti-tuberculosis drug pharmacology. At this meeting, she discussed the "anti-tuberculosis drug Rifampicin Capsule II" She gave a wonderful speech. She first introduced the current situation and causes of the MDR-TB epidemic. New research shows that the 600 mg dose of rifampicin is the “minimum effective dose”. Then Professor Lu learned from the pharmacodynamics of rifampicin. The safety and effectiveness of Rifampicin Capsule II are analyzed in detail in terms of pharmacokinetics, Rifampicin Capsule II’s R&D and characteristics, and the application of Rifampicin Capsule II. Preliminary results of multi-center clinical evaluation of Fuping Capsule II. It is worth mentioning that in his speech, Professor Lu explained the significance of the consistency evaluation of generic drugs, and proposed that Hongqi Pharmaceuticals currently has three varieties passed the consistency evaluation. Experts participating in the conference said that they have gained a lot after listening to Professor Lu's introduction, and they have a more in-depth understanding of rifampicin, and they all expressed their hope to have more opportunities to communicate.
The multi-center clinical evaluation of Rifampicin Capsule II is a study led by the China National Tuberculosis Association, assisted by Shenyang Hongqi Pharmaceutical Co., Ltd., and participated by eight hospitals to evaluate the clinical efficacy of Rifampicin Capsule II and the safety of drug treatment. With a view to providing new options for the use of anti-tuberculosis drugs in my country, the project has entered the stage of writing the final report. The current results show that the use of 450 mg of rifampicin capsule II can achieve the clinical efficacy of 600 mg of rifampicin capsule, with good safety and convenient administration, which is worthy of clinical promotion and use. At the same time, Shenyang Hongqi Pharmaceutical Co., Ltd. now has three varieties (pyrazinamide tablets, rifampicin capsules, isoniazid tablets) that have passed the consistency evaluation of generic drugs. Shenyang Hongqi Pharmaceutical Co., Ltd. is the country's largest anti-tuberculosis drug research and development and The production base, which indicates that the research and development and production of domestic anti-tuberculosis generic drugs have been on the same level as foreign original research drugs, and will provide patients with more choices
